Laboratory Corporation of America Holdings (LH) · Insider trading

What Laboratory Corporation of America Holdings's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months

0 insiders, 0 trades

Sold, 12 months

$13.70M

10 insiders, 60% under a plan

Net, 12 months

−$13.70M

bought less sold

Latest filing

2026-08-18

filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

Bought Sold Largest month: $3.56M

Who traded, two years

Insider	Bought	Sold	Trades	Last trade	Holds after
Schechter Adam HDirector, President & CEO	–	$14.47M	9	2026-08-11	102,565
Anderson Kerrii BDirector	–	$3.77M	8	2026-08-17	6,563
Eisenberg Glenn AExecutive Vice President	–	$2.82M	1	2024-12-02	31,289
van der Vaart Sandra DEVP, Corporate Affairs	–	$2.24M	5	2026-02-27	2,579
Schroeder Mark SEVP, Pres Diagnostics & COO	–	$1.94M	2	2025-03-28	4,960
Parham Richelle PDirector	–	$1.78M	1	2025-10-31	2,469
Wilkinson Peter JSVP, Chief Accounting Officer	–	$1.66M	8	2026-08-03	1,770
Summy Amy B.EVP, Chief Marketing Officer	–	$1.39M	4	2026-08-04	6,956
Caveney Brian JEVP, Pres of ED, CMO & CSO	–	$923,465	2	2026-02-24	30,107
Gilliland Dwight GaryDirector	–	$770,900	2	2025-07-30	6,656
Meltzer Jonathan CEVP, Operations	–	$298,756	4	2026-03-27	3,620
Kyle Kathryn WEVP, Chief Legal Officer	–	$227,414	2	2026-07-02	3,904
Vaughn Bryan TEVP and President, Diagnostics	–	$66,968	1	2026-07-02	6,746

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

Date	Insider	Trade	Shares	Price	Value	Holds after	Filing
2026-08-17	Anderson Kerrii BDirector	Saleplan	3,000	318.02	$954,060	6,563	Form 4
2026-08-11	Schechter Adam HDirector, President & CEO	Saleplan	4,669	320.37	$1.50M	102,565	Form 4
2026-08-04	Summy Amy B.EVP, Chief Marketing Officer	Sale	924	306.74	$283,428	6,956	Form 4
2026-08-03	Wilkinson Peter JSVP, Chief Accounting Officer	Sale	82	309.22	$25,356	1,770	Form 4
2026-08-03	Wilkinson Peter JSVP, Chief Accounting Officer	Sale	1,338	309.23	$413,750	1,770	Form 4
2026-07-02	Vaughn Bryan TEVP and President, Diagnostics	Saleplan	234	286.19	$66,968	6,746	Form 4
2026-07-02	Kyle Kathryn WEVP, Chief Legal Officer	Saleplan	92	286.19	$26,329	3,904	Form 4
2026-06-08	Kyle Kathryn WEVP, Chief Legal Officer	Saleplan	762	263.89	$201,084	3,813	Form 4
2026-05-11	Schechter Adam HDirector, President & CEO	Saleplan	5,903	254.50	$1.50M	107,234	Form 4
2026-03-27	Meltzer Jonathan CEVP, Operations	Saleplan	839	267.05	$224,055	3,620	Form 4
2026-03-27	Wilkinson Peter JSVP, Chief Accounting Officer	Saleplan	1,633	267.05	$436,093	1,852	Form 4
2026-03-03	Schechter Adam HDirector, President & CEO	Sale	8,705	279.96	$2.44M	80,773	Form 4
2026-02-27	van der Vaart Sandra DEVP, Corporate Affairs	Sale	548	284.91	$156,000	2,579	Form 4
2026-02-24	Caveney Brian JEVP, Pres of ED, CMO & CSO	Sale	1,500	286.31	$429,465	30,107	Form 4
2026-02-19	Wilkinson Peter JSVP, Chief Accounting Officer	Saleplan	666	277.94	$185,108	1,852	Form 4
2026-02-12	Meltzer Jonathan CEVP, Operations	Saleplan	87	290.42	$25,267	2,782	Form 4
2026-02-11	Schechter Adam HDirector, President & CEO	Saleplan	5,273	284.38	$1.50M	87,343	Form 4
2026-02-10	Meltzer Jonathan CEVP, Operations	Saleplan	91	276.79	$25,188	2,696	Form 4
2026-02-09	Meltzer Jonathan CEVP, Operations	Saleplan	88	275.53	$24,247	2,869	Form 4
2025-11-11	Schechter Adam HDirector, President & CEO	Saleplan	5,745	262.75	$1.51M	87,574	Form 4
2025-10-31	Parham Richelle PDirector	Sale	7,009	254.28	$1.78M	2,469	Form 4
2025-08-13	van der Vaart Sandra DEVP, Chief Legal Officer	Sale	3,903	271.42	$1.06M	2,274	Form 4
2025-08-11	Schechter Adam HDirector, President & CEO	Saleplan	5,643	266.78	$1.51M	93,319	Form 4
2025-07-30	Gilliland Dwight GaryDirector	Sale	2,000	264.95	$529,900	6,656	Form 4
2025-07-29	Wilkinson Peter JSVP, Chief Accounting Officer	Sale	102	261.01	$26,623	1,952	Form 4
2025-07-29	Wilkinson Peter JSVP, Chief Accounting Officer	Sale	100	261.04	$26,104	1,852	Form 4
2025-07-24	Anderson Kerrii BDirector	Saleplan	3,500	280.00	$980,000	8,666	Form 4
2025-07-24	Anderson Kerrii BDirector	Saleplan	3,500	280.00	$980,000	8,666	Form 4
2025-07-01	Anderson Kerrii BDirector	Saleplan	500	265.00	$132,500	12,166	Form 4
2025-06-11	Anderson Kerrii BDirector	Sale	500	260.00	$130,000	12,666	Form 4
2025-06-03	Caveney Brian JEVP, Pres of ED, CMO & CSO	Sale	2,000	247.00	$494,000	30,067	Form 4
2025-05-12	Schechter Adam HDirector, President & CEO	Saleplan	6,105	248.73	$1.52M	98,962	Form 4
2025-05-01	Wilkinson Peter JSVP, Chief Accounting Officer	Sale	829	242.27	$200,842	2,054	Form 4
2025-05-01	van der Vaart Sandra DEVP, Chief Legal Officer	Sale	1,900	238.36	$452,884	2,244	Form 4
2025-03-28	Schroeder Mark SEVP, Pres Diagnostics & COO	Saleplan	2,635	231.67	$610,450	4,960	Form 4
2025-03-28	Summy Amy B.EVP, Chief Marketing Officer	Saleplan	758	231.67	$175,606	5,302	Form 4
2025-03-05	Anderson Kerrii BDirector	Sale	500	255.63	$127,815	13,166	Form 4
2025-02-28	Schroeder Mark SEVP, Pres Diagnostics & COO	Saleplan	5,339	249.23	$1.33M	4,960	Form 4
2025-02-25	van der Vaart Sandra DEVP, Chief Legal Officer	Sale	1,314	251.30	$330,208	2,171	Form 4
2025-02-24	Summy Amy B.EVP, Chief Marketing Officer	Saleplan	226	250.40	$56,590	4,544	Form 4

9 more

2025-02-18	Wilkinson Peter JSVP, Chief Accounting Officer	Sale	1,413	246.10	$347,739	1,993	Form 4
2025-02-11	Schechter Adam HDirector, President & CEO	Saleplan	6,121	244.62	$1.50M	86,445	Form 4
2025-01-07	Anderson Kerrii BDirector	Saleplan	1,000	235.00	$235,000	12,722	Form 4
2024-12-02	Gilliland Dwight GaryDirector	Sale	1,000	241.00	$241,000	7,712	Form 4
2024-12-02	Eisenberg Glenn AExecutive Vice President	Sale	11,711	240.43	$2.82M	31,289	Form 4
2024-11-22	Summy Amy B.EVP, Chief Marketing Officer	Sale	3,672	238.91	$877,158	4,318	Form 4
2024-11-21	van der Vaart Sandra DEVP, Chief Legal Officer	Sale	1,000	239.42	$239,420	2,670	Form 4
2024-11-11	Schechter Adam HDirector, President & CEO	Saleplan	6,189	243.47	$1.51M	87,441	Form 4
2024-10-24	Anderson Kerrii BDirector	Saleplan	1,000	230.00	$230,000	13,722	Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

107 × option exercise106 × shares withheld for tax23 × grant or award

Show them

Date	Insider	What	Shares	Price	Holds after	Filing
2026-08-03	Wilkinson Peter JSVP, Chief Accounting Officer	Option exercise M	+1,338	209.25	3,108	Form 4
2026-07-01	Vaughn Bryan TEVP and President, Diagnostics	Option exercise M	+327	–	7,073	Form 4
2026-07-01	Vaughn Bryan TEVP and President, Diagnostics	Shares withheld for tax F	−93	283.88	6,980	Form 4
2026-07-01	Kyle Kathryn WEVP, Chief Legal Officer	Option exercise M	+256	–	4,069	Form 4
2026-07-01	Kyle Kathryn WEVP, Chief Legal Officer	Shares withheld for tax F	−73	283.88	3,996	Form 4
2026-03-26	Bailey Megan D.EVP, Pres, Central Labs & Intl	Grant or award A	+1,184	–	5,332	Form 4
2026-03-26	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−481	268.38	4,851	Form 4
2026-03-26	Kyle Kathryn WEVP, Chief Legal Officer	Grant or award A	+1,584	–	5,026	Form 4
2026-03-26	Kyle Kathryn WEVP, Chief Legal Officer	Shares withheld for tax F	−451	268.38	4,575	Form 4
2026-03-26	Meltzer Jonathan CEVP, Operations	Grant or award A	+2,388	–	5,170	Form 4
2026-03-26	Meltzer Jonathan CEVP, Operations	Shares withheld for tax F	−711	268.38	4,459	Form 4
2026-03-26	Oyegunwa AkinboladeEVP, CIO & CTO	Grant or award A	+1,340	–	5,446	Form 4
2026-03-26	Oyegunwa AkinboladeEVP, CIO & CTO	Shares withheld for tax F	−382	268.38	5,064	Form 4
2026-03-26	Summy Amy B.EVP, Chief Marketing Officer	Grant or award A	+3,994	–	9,716	Form 4
2026-03-26	Summy Amy B.EVP, Chief Marketing Officer	Shares withheld for tax F	−1,836	268.38	7,880	Form 4
2026-03-26	van der Vaart Sandra DEVP, Corporate Affairs	Grant or award A	+6,382	–	8,961	Form 4
2026-03-26	van der Vaart Sandra DEVP, Corporate Affairs	Shares withheld for tax F	−2,722	268.38	6,239	Form 4
2026-03-26	Vaughn Bryan TEVP, Diagnostics	Grant or award A	+1,584	–	7,197	Form 4
2026-03-26	Vaughn Bryan TEVP, Diagnostics	Shares withheld for tax F	−451	268.38	6,746	Form 4
2026-03-26	Wilkinson Peter JSVP, Chief Accounting Officer	Grant or award A	+2,388	–	4,240	Form 4
2026-03-26	Wilkinson Peter JSVP, Chief Accounting Officer	Shares withheld for tax F	−755	268.38	3,485	Form 4
2026-03-26	Caveney Brian JEVP, Pres of ED, CMO & CSO	Grant or award A	+9,304	–	39,411	Form 4
2026-03-26	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−4,042	268.38	35,369	Form 4
2026-03-26	Caveney Brian JEVP, Pres of ED, CMO & CSO	Grant or award A	+1,986	–	37,355	Form 4
2026-03-26	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−863	268.38	36,492	Form 4
2026-03-26	Schroeder Mark SEVP, Pres Diagnostics & COO	Grant or award A	+9,304	–	15,777	Form 4
2026-03-26	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−4,600	268.38	11,177	Form 4
2026-03-26	Schroeder Mark SEVP, Pres Diagnostics & COO	Grant or award A	+2,968	–	14,145	Form 4
2026-03-26	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−1,468	268.38	12,677	Form 4
2026-03-26	Graham Anita ZEVP, CHRO	Grant or award A	+6,604	–	8,064	Form 4
2026-03-26	Graham Anita ZEVP, CHRO	Shares withheld for tax F	−2,879	268.38	5,185	Form 4
2026-03-26	Schechter Adam HDirector, President & CEO	Grant or award A	+58,470	–	139,243	Form 4
2026-03-26	Schechter Adam HDirector, President & CEO	Shares withheld for tax F	−26,106	268.38	113,137	Form 4
2026-02-11	Anderson Kerrii BDirector	Option exercise M	+897	–	9,563	Form 4
2026-02-11	Davis Jeffrey A.Director	Option exercise M	+897	–	5,460	Form 4
2026-02-11	Kliphouse Kirsten MarieDirector	Option exercise M	+897	–	3,160	Form 4
2026-02-11	Kong GarhengDirector	Option exercise M	+897	–	13,739	Form 4
2026-02-11	Neupert Peter MDirector	Option exercise M	+897	–	13,784	Form 4
2026-02-11	Parham Richelle PDirector	Option exercise M	+897	–	3,366	Form 4
2026-02-11	Wengel Kathryn EDirector	Option exercise M	+897	–	4,133	Form 4
2026-02-11	Rothman PaulDirector	Option exercise M	+897	–	2,571	Form 4
2026-02-11	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+403	–	4,286	Form 4
2026-02-11	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−138	289.89	4,148	Form 4
2026-02-11	Caveney Brian JEVP, Pres of ED, CMO & CSO	Option exercise M	+740	–	31,818	Form 4
2026-02-11	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−211	289.89	31,607	Form 4
2026-02-11	Graham Anita ZEVP, CHRO	Option exercise M	+356	–	1,569	Form 4
2026-02-11	Graham Anita ZEVP, CHRO	Shares withheld for tax F	−109	289.89	1,460	Form 4
2026-02-11	Kyle Kathryn WEVP, Chief Legal Officer	Option exercise M	+216	–	3,504	Form 4
2026-02-11	Kyle Kathryn WEVP, Chief Legal Officer	Shares withheld for tax F	−62	289.89	3,442	Form 4
2026-02-11	Meltzer Jonathan CEVP, Operations	Option exercise M	+243	–	2,939	Form 4
2026-02-11	Meltzer Jonathan CEVP, Operations	Shares withheld for tax F	−70	289.89	2,869	Form 4
2026-02-11	Oyegunwa AkinboladeEVP, CIO & CTO	Option exercise M	+230	–	4,174	Form 4
2026-02-11	Oyegunwa AkinboladeEVP, CIO & CTO	Shares withheld for tax F	−68	289.89	4,106	Form 4
2026-02-11	Schechter Adam HDirector, President & CEO	Option exercise M	+3,656	–	90,999	Form 4
2026-02-11	Schechter Adam HDirector, President & CEO	Shares withheld for tax F	−1,521	289.89	89,478	Form 4
2026-02-11	Schroeder Mark SEVP, Pres Diagnostics & COO	Option exercise M	+806	–	6,732	Form 4
2026-02-11	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−259	289.89	6,473	Form 4
2026-02-11	van der Vaart Sandra DEVP, Corporate Affairs	Option exercise M	+376	–	3,225	Form 4
2026-02-11	van der Vaart Sandra DEVP, Corporate Affairs	Shares withheld for tax F	−99	289.89	3,126	Form 4
2026-02-11	Vaughn Bryan TEVP, Diagnostics	Option exercise M	+323	–	5,706	Form 4
2026-02-11	Vaughn Bryan TEVP, Diagnostics	Shares withheld for tax F	−93	289.89	5,613	Form 4
2026-02-11	Wang Julia AijunChief Financial Officer, EVP	Option exercise M	+860	–	2,062	Form 4
2026-02-11	Wang Julia AijunChief Financial Officer, EVP	Shares withheld for tax F	−245	289.89	1,817	Form 4
2026-02-11	Wilkinson Peter JSVP, Chief Accounting Officer	Option exercise M	+536	–	2,564	Form 4
2026-02-11	Wilkinson Peter JSVP, Chief Accounting Officer	Shares withheld for tax F	−160	289.89	2,404	Form 4
2026-02-11	Wilkinson Peter JSVP, Chief Accounting Officer	Option exercise M	+160	–	2,564	Form 4
2026-02-11	Wilkinson Peter JSVP, Chief Accounting Officer	Shares withheld for tax F	−46	289.89	2,518	Form 4
2026-02-11	Summy Amy B.EVP, Chief Marketing Officer	Option exercise M	+230	–	5,804	Form 4
2026-02-11	Summy Amy B.EVP, Chief Marketing Officer	Shares withheld for tax F	−83	289.89	5,722	Form 4
2026-02-09	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−85	274.01	3,906	Form 4
2026-02-09	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−23	274.01	3,883	Form 4
2026-02-09	Summy Amy B.EVP, Chief Marketing Officer	Shares withheld for tax F	−80	274.01	5,574	Form 4
2026-02-09	Graham Anita ZEVP, CHRO	Shares withheld for tax F	−112	274.01	1,213	Form 4
2026-02-09	Kyle Kathryn WEVP, Chief Legal Officer	Shares withheld for tax F	−61	274.01	3,288	Form 4
2026-02-09	Meltzer Jonathan CEVP, Operations	Shares withheld for tax F	−82	274.01	2,787	Form 4
2026-02-09	Vaughn Bryan TEVP, Diagnostics	Shares withheld for tax F	−61	274.01	5,383	Form 4
2026-02-09	van der Vaart Sandra DEVP, Corporate Affairs	Shares withheld for tax F	−93	274.01	2,849	Form 4
2026-02-09	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−166	274.01	5,979	Form 4
2026-02-09	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−53	274.01	5,926	Form 4
2026-02-09	Wilkinson Peter JSVP, Chief Accounting Officer	Shares withheld for tax F	−46	274.01	2,028	Form 4
2026-02-09	Schechter Adam HDirector, President & CEO	Shares withheld for tax F	−1,352	274.01	92,616	Form 4
2026-02-09	Oyegunwa AkinboladeEVP, CIO & CTO	Shares withheld for tax F	−51	274.01	3,944	Form 4
2026-02-09	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−148	274.01	31,110	Form 4
2026-02-09	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−32	274.01	31,078	Form 4
2026-02-07	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+222	–	3,924	Form 4
2026-02-07	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+67	–	3,991	Form 4
2026-02-07	Summy Amy B.EVP, Chief Marketing Officer	Option exercise M	+222	–	5,654	Form 4
2026-02-07	Graham Anita ZEVP, CHRO	Option exercise M	+367	–	1,325	Form 4
2026-02-07	Kyle Kathryn WEVP, Chief Legal Officer	Option exercise M	+178	–	3,349	Form 4
2026-02-07	Meltzer Jonathan CEVP, Operations	Option exercise M	+263	–	2,957	Form 4
2026-02-07	Vaughn Bryan TEVP, Diagnostics	Option exercise M	+178	–	5,444	Form 4
2026-02-07	van der Vaart Sandra DEVP, Corporate Affairs	Option exercise M	+353	–	2,942	Form 4
2026-02-07	Schroeder Mark SEVP, Pres Diagnostics & COO	Option exercise M	+517	–	5,981	Form 4
2026-02-07	Schroeder Mark SEVP, Pres Diagnostics & COO	Option exercise M	+164	–	6,145	Form 4
2026-02-07	Wilkinson Peter JSVP, Chief Accounting Officer	Option exercise M	+134	–	2,074	Form 4
2026-02-07	Schechter Adam HDirector, President & CEO	Option exercise M	+3,249	–	93,968	Form 4
2026-02-07	Oyegunwa AkinboladeEVP, CIO & CTO	Option exercise M	+149	–	3,995	Form 4
2026-02-07	Caveney Brian JEVP, Pres of ED, CMO & CSO	Option exercise M	+517	–	31,147	Form 4
2026-02-07	Caveney Brian JEVP, Pres of ED, CMO & CSO	Option exercise M	+111	–	31,258	Form 4
2026-02-06	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+180	–	3,774	Form 4
2026-02-06	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−72	277.20	3,702	Form 4
2026-02-06	Summy Amy B.EVP, Chief Marketing Officer	Option exercise M	+223	–	5,524	Form 4
2026-02-06	Summy Amy B.EVP, Chief Marketing Officer	Shares withheld for tax F	−92	277.20	5,432	Form 4
2026-02-06	Graham Anita ZEVP, CHRO	Option exercise M	+327	–	1,077	Form 4
2026-02-06	Graham Anita ZEVP, CHRO	Shares withheld for tax F	−119	277.20	958	Form 4
2026-02-06	Kyle Kathryn WEVP, Chief Legal Officer	Option exercise M	+180	–	3,232	Form 4
2026-02-06	Kyle Kathryn WEVP, Chief Legal Officer	Shares withheld for tax F	−61	277.20	3,171	Form 4
2026-02-06	Meltzer Jonathan CEVP, Operations	Option exercise M	+267	–	2,785	Form 4
2026-02-06	Meltzer Jonathan CEVP, Operations	Shares withheld for tax F	−91	277.20	2,694	Form 4
2026-02-06	Vaughn Bryan TEVP, Diagnostics	Option exercise M	+180	–	5,327	Form 4
2026-02-06	Vaughn Bryan TEVP, Diagnostics	Shares withheld for tax F	−61	277.20	5,266	Form 4
2026-02-06	van der Vaart Sandra DEVP, Corporate Affairs	Option exercise M	+387	–	2,690	Form 4
2026-02-06	van der Vaart Sandra DEVP, Corporate Affairs	Shares withheld for tax F	−101	277.20	2,589	Form 4
2026-02-06	Schroeder Mark SEVP, Pres Diagnostics & COO	Option exercise M	+743	–	5,703	Form 4
2026-02-06	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−239	277.20	5,464	Form 4
2026-02-06	Wilkinson Peter JSVP, Chief Accounting Officer	Option exercise M	+133	–	1,985	Form 4
2026-02-06	Wilkinson Peter JSVP, Chief Accounting Officer	Shares withheld for tax F	−45	277.20	1,940	Form 4
2026-02-06	Schechter Adam HDirector, President & CEO	Option exercise M	+4,460	–	92,034	Form 4
2026-02-06	Schechter Adam HDirector, President & CEO	Shares withheld for tax F	−1,315	277.20	90,719	Form 4
2026-02-06	Oyegunwa AkinboladeEVP, CIO & CTO	Option exercise M	+180	–	3,907	Form 4
2026-02-06	Oyegunwa AkinboladeEVP, CIO & CTO	Shares withheld for tax F	−61	277.20	3,846	Form 4
2026-02-06	Caveney Brian JEVP, Pres of ED, CMO & CSO	Option exercise M	+670	–	30,839	Form 4
2026-02-06	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−209	277.20	30,630	Form 4
2026-02-06	Wang Julia AijunChief Financial Officer, EVP	Option exercise M	+893	–	1,456	Form 4
2026-02-06	Wang Julia AijunChief Financial Officer, EVP	Shares withheld for tax F	−254	277.20	1,202	Form 4
2025-11-03	Oyegunwa AkinboladeEVP, CIO & CTO	Shares withheld for tax F	−107	257.84	3,727	Form 4
2025-11-03	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−179	257.84	3,594	Form 4
2025-11-01	Oyegunwa AkinboladeEVP, CIO & CTO	Option exercise M	+370	–	3,834	Form 4
2025-11-01	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+370	–	3,773	Form 4
2025-08-13	van der Vaart Sandra DEVP, Chief Legal Officer	Option exercise M	+3,903	131.43	6,177	Form 4
2025-04-01	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+4,083	–	4,813	Form 4
2025-04-01	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−1,546	232.65	3,267	Form 4
2025-04-01	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+204	–	3,471	Form 4
2025-04-01	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−68	232.65	3,403	Form 4
2025-03-27	Oyegunwa AkinboladeEVP, CIO & CTO	Grant or award A	+688	–	3,662	Form 4
2025-03-27	Oyegunwa AkinboladeEVP, CIO & CTO	Shares withheld for tax F	−198	231.67	3,464	Form 4
2025-03-27	Wilkinson Peter JSVP, Chief Accounting Officer	Grant or award A	+1,249	–	3,242	Form 4
2025-03-27	Wilkinson Peter JSVP, Chief Accounting Officer	Shares withheld for tax F	−359	231.67	2,883	Form 4
2025-03-27	Caveney Brian JEVP, Pres of ED, CMO & CSO	Grant or award A	+4,840	–	34,176	Form 4
2025-03-27	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−2,109	231.67	32,067	Form 4
2025-03-27	Berberian LanceEVP, Special Advisor, Strategy	Grant or award A	+3,325	–	20,005	Form 4
2025-03-27	Berberian LanceEVP, Special Advisor, Strategy	Shares withheld for tax F	−1,353	231.67	18,652	Form 4
2025-03-27	Eisenberg Glenn AExecutive Vice President	Grant or award A	+8,305	–	41,550	Form 4
2025-03-27	Eisenberg Glenn AExecutive Vice President	Shares withheld for tax F	−3,630	231.67	37,920	Form 4
2025-03-27	Schechter Adam HDirector, President & CEO	Grant or award A	+30,469	–	118,651	Form 4
2025-03-27	Schechter Adam HDirector, President & CEO	Shares withheld for tax F	−13,584	231.67	105,067	Form 4
2025-03-27	van der Vaart Sandra DEVP, Chief Legal Officer	Grant or award A	+3,325	–	5,496	Form 4
2025-03-27	van der Vaart Sandra DEVP, Chief Legal Officer	Shares withheld for tax F	−1,352	231.67	4,144	Form 4
2025-03-27	Schroeder Mark SEVP, Pres Diagnostics & COO	Grant or award A	+4,840	–	9,800	Form 4
2025-03-27	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−2,205	231.67	7,595	Form 4
2025-03-27	Summy Amy B.EVP, Chief Marketing Officer	Grant or award A	+2,077	–	6,622	Form 4
2025-03-27	Summy Amy B.EVP, Chief Marketing Officer	Shares withheld for tax F	−562	231.67	6,060	Form 4
2025-02-28	Schroeder Mark SEVP, Pres Diagnostics & COO	Option exercise M	+3,903	131.43	10,299	Form 4
2025-02-18	Wilkinson Peter JSVP, Chief Accounting Officer	Option exercise M	+1,413	163.63	3,406	Form 4
2025-02-11	Oyegunwa AkinboladeEVP, CIO & CTO	Option exercise M	+134	–	3,016	Form 4
2025-02-11	Oyegunwa AkinboladeEVP, CIO & CTO	Shares withheld for tax F	−42	245.14	2,974	Form 4
2025-02-11	Schroeder Mark SEVP, Pres Diagnostics & COO	Option exercise M	+473	–	6,530	Form 4
2025-02-11	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−134	245.14	6,396	Form 4
2025-02-11	van der Vaart Sandra DEVP, Chief Legal Officer	Option exercise M	+323	–	3,571	Form 4
2025-02-11	van der Vaart Sandra DEVP, Chief Legal Officer	Shares withheld for tax F	−86	245.14	3,485	Form 4
2025-02-11	Caveney Brian JEVP, Pres of ED, CMO & CSO	Option exercise M	+473	–	29,472	Form 4
2025-02-11	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−136	245.14	29,336	Form 4
2025-02-11	Berberian LanceEVP, Special Advisor, Strategy	Option exercise M	+323	–	16,766	Form 4
2025-02-11	Berberian LanceEVP, Special Advisor, Strategy	Shares withheld for tax F	−86	245.14	16,680	Form 4
2025-02-11	Eisenberg Glenn AExecutive Vice President	Option exercise M	+807	–	33,458	Form 4
2025-02-11	Eisenberg Glenn AExecutive Vice President	Shares withheld for tax F	−213	245.14	33,245	Form 4
2025-02-11	Schechter Adam HDirector, President & CEO	Option exercise M	+2,963	–	89,408	Form 4
2025-02-11	Schechter Adam HDirector, President & CEO	Shares withheld for tax F	−1,226	245.14	88,182	Form 4
2025-02-11	Summy Amy B.EVP, Chief Marketing Officer	Option exercise M	+201	–	4,826	Form 4
2025-02-11	Summy Amy B.EVP, Chief Marketing Officer	Shares withheld for tax F	−55	245.14	4,770	Form 4
2025-02-11	Wilkinson Peter JSVP, Chief Accounting Officer	Option exercise M	+123	–	2,385	Form 4
2025-02-11	Wilkinson Peter JSVP, Chief Accounting Officer	Shares withheld for tax F	−41	245.14	2,344	Form 4
2025-02-07	Graham Anita ZEVP, CHRO	Option exercise M	+369	–	869	Form 4
2025-02-07	Graham Anita ZEVP, CHRO	Shares withheld for tax F	−119	246.27	750	Form 4
2025-02-07	van der Vaart Sandra DEVP, Chief Legal Officer	Option exercise M	+354	–	3,342	Form 4
2025-02-07	van der Vaart Sandra DEVP, Chief Legal Officer	Shares withheld for tax F	−94	246.27	3,248	Form 4
2025-02-07	Schechter Adam HDirector, President & CEO	Option exercise M	+3,250	–	93,911	Form 4
2025-02-07	Schechter Adam HDirector, President & CEO	Shares withheld for tax F	−1,345	246.27	92,566	Form 4
2025-02-07	Wilkinson Peter JSVP, Chief Accounting Officer	Option exercise M	+134	–	2,308	Form 4
2025-02-07	Wilkinson Peter JSVP, Chief Accounting Officer	Shares withheld for tax F	−46	246.27	2,262	Form 4
2025-02-07	Schroeder Mark SEVP, Pres Diagnostics & COO	Option exercise M	+517	–	6,086	Form 4
2025-02-07	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−146	246.27	5,940	Form 4
2025-02-07	Schroeder Mark SEVP, Pres Diagnostics & COO	Option exercise M	+164	–	6,104	Form 4
2025-02-07	Schroeder Mark SEVP, Pres Diagnostics & COO	Shares withheld for tax F	−47	246.27	6,057	Form 4
2025-02-07	Summy Amy B.EVP, Chief Marketing Officer	Option exercise M	+224	–	4,692	Form 4
2025-02-07	Summy Amy B.EVP, Chief Marketing Officer	Shares withheld for tax F	−68	246.27	4,624	Form 4
2025-02-07	Oyegunwa AkinboladeEVP, CIO & CTO	Option exercise M	+149	–	2,933	Form 4
2025-02-07	Oyegunwa AkinboladeEVP, CIO & CTO	Shares withheld for tax F	−51	246.27	2,882	Form 4
2025-02-07	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+224	–	770	Form 4
2025-02-07	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−85	246.27	685	Form 4
2025-02-07	Bailey Megan D.EVP, Pres, Central Labs & Intl	Option exercise M	+67	–	752	Form 4
2025-02-07	Bailey Megan D.EVP, Pres, Central Labs & Intl	Shares withheld for tax F	−22	246.27	730	Form 4
2025-02-07	Caveney Brian JEVP, Pres of ED, CMO & CSO	Option exercise M	+517	–	29,069	Form 4
2025-02-07	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−149	246.27	28,920	Form 4
2025-02-07	Caveney Brian JEVP, Pres of ED, CMO & CSO	Option exercise M	+112	–	29,032	Form 4
2025-02-07	Caveney Brian JEVP, Pres of ED, CMO & CSO	Shares withheld for tax F	−33	246.27	28,999	Form 4
2025-02-07	Berberian LanceEVP, Special Advisor, Strategy	Option exercise M	+354	–	16,537	Form 4
2025-02-07	Berberian LanceEVP, Special Advisor, Strategy	Shares withheld for tax F	−94	246.27	16,443	Form 4
2025-02-07	Eisenberg Glenn AExecutive Vice President	Option exercise M	+885	–	32,885	Form 4
2025-02-07	Eisenberg Glenn AExecutive Vice President	Shares withheld for tax F	−234	246.27	32,651	Form 4

How to read it

Buy, sale: Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan: A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after: The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value: Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

Laboratory Corporation of America Holdings's scores and multiples ›